Editing Exelixis (section)

{{short description|American biotechnology company}}
{{Infobox company
| name = Exelixis, Inc.
| logo = Exelixis logo.svg
| former_name = {{nowrap|Exelixis Pharmaceuticals, Inc.}}<br>{{small|(1994-2000)}}
| type = [[Public company|Public]]
| traded_as = {{ubl|{{NASDAQ|EXEL}}|[[List of S&P 400 companies|S&P 400]] component}}
| industry = [[Biotechnology]]
| foundation = {{start date and age|1994|11}}
| location = [[Alameda, California]], U.S.
| key_people = Stelios Papadopoulos, Ph.D. ([[chairman]])<br>Michael M. Morrissey, Ph.D. ([[President (corporate title)|president]] & [[Chief executive officer|CEO]])<ref name="marketwatch">{{cite web|url=https://www.marketwatch.com/investing/stock/exel/profile |title=Exelixis Inc. Profile |access-date=January 6, 2020 |website=MarketWatch.com}}</ref>
| revenue = {{nowrap|{{increase}} [[US$]] 1.435 Billion {{small|(2021)}}}}<ref>{{Cite web|url=https://www.macrotrends.net/stocks/charts/EXEL/exelixis/revenue|title = Exelixis Revenue 2010-2022}}</ref>
| operating_income = {{nowrap|{{increase}} [[US$]] 0.287 Billion {{small|(2021)}}}}<ref>{{Cite web|url=https://www.macrotrends.net/stocks/charts/EXEL/exelixis/operating-income|title = Exelixis Operating Income 2010-2022}}</ref>
| net_income = {{nowrap|{{increase}} [[US$]] 0.231 Billion {{small|(2021)}}}}<ref>{{Cite web|url=https://www.macrotrends.net/stocks/charts/EXEL/exelixis/net-income|title = Exelixis Net Income 2010-2022}}</ref>
| assets = {{nowrap|{{increase}} [[US$]] 2.61 Billion {{small|(2021)}}}}<ref>{{Cite web|url=https://www.macrotrends.net/stocks/charts/EXEL/exelixis/total-assets|title = Exelixis Total Assets 2010-2022}}</ref>
| equity = {{nowrap|{{increase}} [[US$]] 2.211 Billion {{small|(2021)}}}}<ref>{{Cite web|url=https://www.macrotrends.net/stocks/charts/EXEL/exelixis/total-share-holder-equity|title = Exelixis Share Holder Equity 2010-2022}}</ref>
| num_employees = {{nowrap|954 {{small|(2021)}}<ref>{{cite web|url=https://www.macrotrends.net/stocks/charts/EXEL/exelixis/number-of-employees|title=Exelixis: Number of Employees 2010-2022}}</ref>}}
| website = {{URL|exelixis.com}}
| footnotes = <ref name="10-K 2021">{{cite web|url=https://www.sec.gov/ix?doc=/Archives/edgar/data/0000939767/000093976722000026/exel-20211231.htm|title=US SEC: Form 10-K Exelixis, Inc.|publisher=[[U.S. Securities and Exchange Commission]]|accessdate=November 3, 2021}}</ref>
}}

'''Exelixis, Inc.''' is a [[genomics]]-based drug discovery company located in [[Alameda County, California|Alameda]], California, and the producer of [[Cometriq]], a treatment approved by the U.S. [[Food and Drug Administration]] (FDA) for [[medullary thyroid cancer]] with clinical activity in several other types of metastatic cancer.